Kathryn Guarini
Known title: DirectorCIK: 0001992352
Associated companies
Transaction History
| REGN | ▲ Buy | Option Exercise | 400 | $288K | 9/2/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 400 | $340K | 9/2/2026 | View on chart |
| REGN | ▲ Buy | Option Exercise | 400 | $288K | 8/10/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 400 | $320K | 8/10/2026 | View on chart |
| REGN | ▲ Buy | Grant | 155 | $0 | 1/2/2026 | View on chart |
| REGN | ▲ Buy | Grant | 166 | $0 | 1/2/2025 | View on chart |
| REGN | ▲ Buy | Grant | 42 | $0 | 1/2/2024 | View on chart |
| REGN | ▲ Buy | Grant | 240 | $0 | 9/8/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.